Mizushima E, Tsukahara T, Emori M, et al. Osteosarcoma‐initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B. Cancer Sci. 2020;111:36--46. 10.1111/cas.14229

1. INTRODUCTION {#cas14229-sec-0001}
===============

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Most osteosarcoma cases are high‐grade and some are resistant to conventional chemotherapy.[1](#cas14229-bib-0001){ref-type="ref"} Therefore, the development of novel treatments is needed.

Previous studies have shown that several human cancers have a small subpopulation of cells called cancer stem‐like cells or cancer‐initiating cells (CIC), which are characterized by self‐renewal capacity, differentiation potential, and cancer‐initiating ability.[2](#cas14229-bib-0002){ref-type="ref"}, [3](#cas14229-bib-0003){ref-type="ref"} Sarcoma‐initiating cells (SIC) with features similar to those of CIC have also been observed in sarcomas. SIC are thought to play a role in recurrence and metastasis, and it is therefore important to develop a treatment strategy targeting SIC for sarcomas.[4](#cas14229-bib-0004){ref-type="ref"}

Cancer metabolism has recently attracted much attention.[5](#cas14229-bib-0005){ref-type="ref"} The metabolic plasticity of cancer is involved in its progression, drug resistance, and metastasis.[6](#cas14229-bib-0006){ref-type="ref"} Cancer cells generate an enormous amount of energy for their survival by glycolysis in an aerobic microenvironment, the so‐called Warburg effect.[7](#cas14229-bib-0007){ref-type="ref"} Aguilar et al reported that glycolysis is essential for CIC;[8](#cas14229-bib-0008){ref-type="ref"} however, the role of cell metabolism in CIC and SIC remains unknown.

In the present study, we established a new osteosarcoma cell line (OS13) and isolated clones based on higher and lower growth capacity (OS^HIGH^ and OS^LOW^ cells, respectively). OS^HIGH^ cells had the characteristics of SIC. Using next‐generation sequencing, we identified *LIN28B*, which was expressed at a higher level in OS^HIGH^ cells than in OS^LOW^ cells. Silencing of *LIN28B* changed the metabolism of osteosarcoma and induced the loss of SIC characteristics.

2. MATERIALS AND METHODS {#cas14229-sec-0002}
========================

Mice were maintained and experimented on in accordance with the guidelines of the ethics committee of Sapporo Medical University School of Medicine, Animal Experimentation Center (permit number 15‐070). Any animal found to be unhealthy or sick was promptly killed. The study was approved by the Institutional Review Board of Sapporo Medical University. Written informed consent was obtained from all patients according to the guidelines of the Declaration of Helsinki.

2.1. Establishment of cell lines {#cas14229-sec-0003}
--------------------------------

The biopsy specimen of a conventional osteosarcoma in the distal femur of a 15‐year‐old girl was minced and cultured with Iscove's Modified Dulbecco's Medium (IMDM; Gibco BRL), containing 10% FBS in a 5% CO~2~ incubator. After 1 year of continuous passages, a cell line was established and designated OS13.

2.2. Cell lines and culture {#cas14229-sec-0004}
---------------------------

Human osteosarcoma cell lines (OS2000, KIKU, OS13, HOS, U2OS, and HuO9), and one human bone malignant fibrous histiocytoma cell line (MFH03) were used. OS2000, KIKU, and MFH03 were established in our laboratory.[9](#cas14229-bib-0009){ref-type="ref"}, [10](#cas14229-bib-0010){ref-type="ref"}, [11](#cas14229-bib-0011){ref-type="ref"} The other cell lines were purchased from the Japanese Collection of Research Bioresources Cell Bank and from the ATCC. OS2000 and MFH03 cells were cultured in IMDM containing 10% FBS and the others were cultured in DMEM (Sigma‐Aldrich) containing 10% FBS in a 5% CO~2~ incubator.

2.3. Clonal sphere formation assay after limiting dilution {#cas14229-sec-0005}
----------------------------------------------------------

OS13 cells were seeded in a flat‐bottom 96‐well culture plate under the condition of limiting dilution. Subsequently, the sphere‐forming ability of each clone was assessed as follows. Clonal cells were plated at 500 cells/well in six‐well ultra‐low attachment plates (Corning Inc.) and cultured in serum‐free IMDM with 10 ng/mL recombinant human epidermal growth factor, 10 ng/mL human basic fibroblast growth factor, 1% penicillin and streptomycin, and 2% B‐27 supplement (Life Technologies Corp.). On day 8, numbers of colonies were counted.

2.4. Xenograft model {#cas14229-sec-0006}
--------------------

Mice had free access to food and water and were housed in sterile cages containing wood shavings and bedding under a 12‐h light/dark cycle with a controlled room temperature. Cells (1 × 10^2^, 1 × 10^3^, and 1 × 10^4^) were suspended in 100 μL PBS and mixed with Matrigel (BD Biosciences) in a 1:1 volume ratio. This mixture was s.c. injected into the backs of 4‐week‐old non‐obese diabetic/scid IL2ry^null^ (NSG) mice (male and female, NOD.Cg‐*Prkdc^scid^* *Il2* *rg^tm1Wjl^*/SzJ; The Jackson Laboratory) under anesthesia using isoflurane inhalation. Tumor sizes were evaluated three times per week for 7 weeks. For the in vivo treatment model, sarcoma cells (1 × 10^6^ cells) were suspended in 50 μL PBS and mixed with Matrigel in a 1:1 volume on day 0. This mixture was s.c. injected into the backs of the NSG mice (4 to 20 weeks old, male and female) under anesthesia. The mice were randomly assigned to experimental groups. Tumor size was evaluated three times per week for 7 weeks. From day 0, Adriamycin (Sandoz) was given i.p. once a week for 3 weeks. Additionally, from day 0, glycolysis inhibitors (2‐deoxyglucose \[2‐DG\] and dichloroacetate \[DCA\]) were given i.p. three times per week for 6 weeks. No anesthesia was needed to give the drugs. At the endpoint, mice were killed by cervical dislocation under anesthesia.

2.5. Chemoresistance assay {#cas14229-sec-0007}
--------------------------

Effects of a chemotherapy agent on the high clone and low clone cells were evaluated using CCK‐8 (Dojindo) according to the manufacturer's protocol. The clone cells were plated at 15,000 cells/well in a 96‐well plate with 100 μL culture medium. After 24 hours, the culture medium was replaced and Adriamycin was directly added at various concentrations. After 24‐h treatment, the cells were incubated with 10 μL CCK‐8 reagent for 4 hours at 37°C in a 5% CO~2~ incubator. Absorbance at 450 nm was measured with a Bio‐Rad ELISA reader (Bio‐Rad).

2.6. Reverse transcription‐PCR {#cas14229-sec-0008}
------------------------------

Total RNA was extracted from clone cells using the RNeasy Mini Kit (Qiagen) with DNase I treatment and reverse‐transcribed using SuperScript III (Invitrogen) according to the manufacturer's protocol. RT‐PCR was carried out with Taq DNA polymerase (Qiagen) using forward primer 5′‐AGCCCCTTGGATATTCCAGTC‐3′ and reverse primer 5′‐AATGTGAATTCCACTGGTTCTCCT‐3′ for LIN28B. The PCR mixture was denatured at 94°C for 2 minutes, followed by 30 cycles at 94°C for 15 seconds, 58°C for 30 seconds, and 72°C for 30 seconds. Quantitative PCR was carried out using a StepOne Real‐Time PCR system (Applied Biosystems). LIN28B (Hs01013729_m1), SOX2 (Hs01053049_s1), POU5F1 (Hs00999632_g1), and NANOG (Hs04260366_g1) primers and probes were designed using the TaqMan Gene Expression assay (Applied Biosystems). Human normal tissue panels (Human MTC panels I and II; Takara Bio. Inc.) were used as normal tissue. Each experiment was carried out in triplicate and normalized to the GAPDH gene as an internal control. miRNAs were extracted using the mirVana miRNA Isolation Kit (Ambion) according to the manufacturer's protocol. Mature let‐7a and let‐7g were quantified using a predesignated TaqMan MicroRNA Assay (Applied Biosystems).

2.7. Next‐generation sequencing {#cas14229-sec-0009}
-------------------------------

Total RNAs were extracted from cells using the RNeasy Mini Kit followed by sequencing with Illumina Hiseq 2500 and analyzed by Hokkaido System Science Co., Ltd. Gene ontology enrichment analysis was carried out for differentially expressed genes using DAVID, the database of the National Institute of Allergy and Infectious Diseases.

2.8. Immunohistochemistry {#cas14229-sec-0010}
-------------------------

Immunohistochemical staining was done using formalin‐fixed paraffin‐embedded sections of biopsy specimens from 40 sarcoma patients as previously described.[12](#cas14229-bib-0012){ref-type="ref"} A rabbit anti‐lin28B polyclonal antibody (ab71415; Abcam) was used at a 1:200 dilution. Reactivity of the anti‐lin28B antibody was determined by the staining pattern of the nuclei and cytosol of tumor cells. Cases were graded as follows: negative (\<5% positive cells), low (5%--50% positive cells), and high (\>50% positive cells).

2.9. LIN28B knockdown {#cas14229-sec-0011}
---------------------

LIN28B shRNA in a lentiviral plasmid (TRCN0000122599) and control shRNA (SHC002V) were used according to the manufacturer's protocol (Sigma‐Aldrich). Briefly, OS13 cells were infected with lentiviral transduction particles at a MOI of 1.0 in the presence of polybrene (8 ng/µL). Infected cells were selected by a puromycin antibiotic prior to the analysis.

2.10. Western blotting {#cas14229-sec-0012}
----------------------

Cells were suspended in ice‐cold RIPA buffer for 10 minutes. The lysates were mixed with 2 × sample buffer and boiled for 5 minutes. Lysates were separated on 10% SDS‐PAGE and transferred to PVDF membranes (Immobilon‐P Transfer Membranes; Merck). The membranes were incubated primarily with rabbit anti‐LIN28B monoclonal antibody (ab191881; Abcam) or mouse anti‐β‐actin monoclonal antibody (clone AC‐15; Sigma‐Aldrich) for 1 hour at room temperature. Membranes were then stained with a peroxidase‐labeled secondary antibody and visualized with an ECL detection system (GE Healthcare).

2.11. Metabolic analysis {#cas14229-sec-0013}
------------------------

Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined by a Seahorse XF24 analyzer (Agilent Technologies, Inc.). Cells were plated at 15,000 cells/well in XF24‐well plates. The next day, the cells were washed and equilibrated with an assay medium for 30 minutes at 37°C in a CO~2~‐free incubator. Initial measurements of OCR and ECAR were carried out before the addition of glucose. Subsequent measurements were done after 25 mM glucose had been added into the wells through injection ports. Three types of reagent were subsequently added to evaluate mitochondrial respiration capacity. Oligomycin (Agilent Technologies, Inc.) is an inhibitor of oxidative phosphorylation (OXPHOS); flavin adenine dinucleotide (FCCP; Agilent Technologies, Inc.) is an accelerator of the electron transport chain by perforation of the inner mitochondrial membrane; and rotenone and antimycin‐A (Agilent Technologies, Inc.) are inhibitors of the mitochondrial NADH dehydrogenase/complex.

2.12. Aerobic glycolysis inhibition {#cas14229-sec-0014}
-----------------------------------

Sphere formation assays were carried out in culture media with either no glucose or a high concentration of glucose. Serum‐free DMEM (Nacalai Tesque, Inc.) containing 25 mM glucose was used as the high glucose medium. 2‐DG (Sigma‐Aldrich) and DCA (Sigma‐Aldrich) were used at final concentrations of 10 mM each.

2.13. Measurement of ATP production {#cas14229-sec-0015}
-----------------------------------

ATP levels were measured using a Cellno ATP Assay Kit (Toyo B‐Net Co., Ltd) according to the manufacturer's protocol. Prior to measurement, cells were cultured in IMDM medium with or without reagents for 45 minutes. Luminescence intensity was measured using an Infinite M1000 Pro plate reader (Tecan).

2.14. Statistical analysis {#cas14229-sec-0016}
--------------------------

For comparisons, we used the unpaired *t* test in JMP software (SAS Institute Inc.). Where relevant, figures indicate statistical parameters, including the value of n, means ± SD, and statistical significance.

3. RESULTS {#cas14229-sec-0017}
==========

3.1. Establishment of the osteosarcoma cell line OS13 {#cas14229-sec-0018}
-----------------------------------------------------

A tumor cell culture was maintained for 1 year and designated OS13. Biopsy specimens showed the presence of pleomorphic cells with atypical nuclei in neoplastic bones (Figure [S1](#cas14229-sup-0001){ref-type="supplementary-material"}A). Karyotype analysis of OS13 showed multiple numerical and structural chromosomal aberrations (Figure [S1](#cas14229-sup-0001){ref-type="supplementary-material"}B). Subcutaneous inoculation of OS13 cells into the NSG mice resulted in the formation of malignant tumors. Histologically, the xenografted tumors consisted of pleomorphic cells; however, no neoplastic bone was seen (Figure [S1](#cas14229-sup-0001){ref-type="supplementary-material"}C).

3.2. Identification of a clone that showed higher tumorigenicity as SIC {#cas14229-sec-0019}
-----------------------------------------------------------------------

Previously, we isolated SIC from sarcoma cell lines using the side population and ALDEFLUOR assays based on activity of the drug efflux ATP‐binding cassette ABCG2 and aldehyde dehydrogenase activity, respectively.[13](#cas14229-bib-0013){ref-type="ref"}, [14](#cas14229-bib-0014){ref-type="ref"} However, we could not separate the populations of SIC and non‐SIC using these methods. Therefore, we attempted to establish a single cell clone by limiting dilution to separate SIC and non‐SIC among OS13 bulk cells. Sphere‐formation ability of the resultant 54 clones was subsequently assessed to isolate clones showing higher and lower tumorigenesis. Surprisingly, most of the clones showed higher tumorigenesis (Figure [S2](#cas14229-sup-0001){ref-type="supplementary-material"}), suggesting that OS13 bulk cells contained a very large proportion of SIC. Finally, we selected clones with higher tumorigenicity as SIC (OS^HIGH^) and clones with lower tumorigenicity as non‐SIC (OS^LOW^). As shown in Figure [1](#cas14229-fig-0001){ref-type="fig"}A--C, the OS^HIGH^ cells formed many large spheres, whereas the OS^LOW^ cells formed only a few small colonies.

![Characteristics of osteosarcoma (OS)^HIGH^ cells as sarcoma‐initiating cells. Features of spherical colonies from clones with higher tumorigenesis as sarcoma‐initiating cells (OS^HIGH^ cells) (A) and clones with lower tumorigenesis as sarcoma‐initiating cells (OS^LOW^ cells) (B). Original magnification, 100×. C, Number of spheres from OS^HIGH^ and OS^LOW^ cells (n = 3). D, Tumorigenesis of OS^HIGH^ cells (A) and OS^LOW^ cells. Cells were injected into the s.c. spaces in the backs of non‐obese diabetic/scid IL2ry^null^ (NSG) mice. Injections of 1 × 10^3^ cells result in tumor formation at 7 weeks. E, Macroscopic features of xenografted tumors comprising OS^HIGH^ and OS^LOW^ cells in NSG mice. Circle indicates tumor derived from OS^HIGH^ cells. F, Tumor growth curves of OS^HIGH^ and OS^LOW^ cells. Data represent means ± standard error (SE). G, Cell viability rates of both clones with Adriamycin (Sandoz) treatment (n = 3). H, Quantitative RT‐PCR of stem cell‐related genes in both clones. Data represent means ± SE. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001. N.S., not significant](CAS-111-36-g001){#cas14229-fig-0001}

To assess tumorigenesis in vivo, 1 × 10^2^ to 1 × 10^4^ clone cells were injected into the NSG mice. Tumor formation was observed in two of three mice that received 10^2^ OS^HIGH^ cells but in only one of three mice that received 10^2^ OS^LOW^ cells (Figure [1](#cas14229-fig-0001){ref-type="fig"}D). Following injections of more than 10^3^ cells, OS^HIGH^ cells formed a larger tumor mass than that formed by OS^LOW^ cells (Figure [1](#cas14229-fig-0001){ref-type="fig"}E,F). OS^HIGH^ cells also showed higher resistance to Adriamycin, a key drug used in chemotherapy for osteosarcoma (Figure [1](#cas14229-fig-0001){ref-type="fig"}G). These results indicated that OS^HIGH^ cells and OS^LOW^ cells have characteristics of SIC and non‐SIC, respectively. However, OS^HIGH^ cells showed expression levels of stem cell‐related genes including *SOX2*, *NANOG*, and *POU5F1* that were similar to those in OS^LOW^ cells (Figure [1](#cas14229-fig-0001){ref-type="fig"}H).

3.3. OS^HIGH^ cells were dependent on aerobic glycolysis and attenuation of mitochondrial function {#cas14229-sec-0020}
--------------------------------------------------------------------------------------------------

Oxygen consumption rate and ECAR were determined to assess the metabolic features of OS^HIGH^ and OS^LOW^ cells. OCR was significantly decreased in OS^HIGH^ cells compared with OS^LOW^ cells (Figure [2](#cas14229-fig-0002){ref-type="fig"}A). In contrast, both OS^LOW^ and OS^HIGH^ cells were highly dependent on aerobic glycolysis (Figure [2](#cas14229-fig-0002){ref-type="fig"}B). After injections of glucose, OCR of OS^LOW^ cells increased, whereas that of OS^HIGH^ cells decreased (Figure [2](#cas14229-fig-0002){ref-type="fig"}C). ECAR rapidly increased in both OS^LOW^ and OS^HIGH^ cells (Figure [2](#cas14229-fig-0002){ref-type="fig"}D). Next, the activity of mitochondria was assessed (Figure [2](#cas14229-fig-0002){ref-type="fig"}E,F). Treatment of the cells with oligomycin, which partially downregulates mitochondrial respiration, resulted in a decrease in the OCR of OS^LOW^ cells and a slight decrease in that of OS^HIGH^ cells. OCR of both clones increased in response to treatment with FCCP and decreased in response to treatment with rotenone and antimycin‐A, which completely inhibited mitochondrial respiration. OS^LOW^ cells responded to the reagents, but OS^HIGH^ cells showed only slight changes in OCR. ECAR of both clones increased similarly in response to the reagents. These results suggested that OS^LOW^ cells have functional mitochondria. Therefore, OS^HIGH^ might be more dependent than OS^LOW^ cells on glycolysis for the generation of ATP. In contrast, OS^LOW^ cells use both aerobic glycolysis and OXPHOS in mitochondria.

![Osteosarcoma (OS)^HIGH^ cells depend on aerobic glycolysis. Basal mitochondrial respiration rates (A) and glycolysis rates (B) of clones with higher tumorigenesis as sarcoma‐initiating cells (OS^HIGH^ cells) and clones with lower tumorigenesis as sarcoma‐initiating cells (OS^LOW^ cells) (OS^HIGH^, n = 6; OS^LOW^, n = 6). Data represent means ± standard error (SE). \*\**P* \< .001. N.S., not significant. Real‐time analysis of oxygen consumption rate (OCR) (C) and extracellular acidification rate (ECAR) (D) after 25 mM injection of glucose. Dotted lines indicate injections of each reagent (OS^HIGH^, n = 6; OS^LOW^, n = 6). Analysis of OCR (E) and ECAR (F) after the addition of oligomycin, flavin adenine dinucleotide (FCCP), rotenone, and antimycin‐A. Dotted lines indicate injections of each reagent (OS^HIGH^, n = 6; OS^LOW^, n = 6). Data represent means ± SE](CAS-111-36-g002){#cas14229-fig-0002}

3.4. Identification of LIN28B as a SIC‐related gene {#cas14229-sec-0021}
---------------------------------------------------

We carried out gene expression profiling of both clones using RNA‐sequencing. Numerous genes were found to be upregulated in OS^HIGH^ cells compared with OS^LOW^ cells. Gene ontology enrichment analysis showed that the gene signature of OS^HIGH^ cells was significantly related to nucleosome organization or cell reproduction (Table [S1](#cas14229-sup-0002){ref-type="supplementary-material"}). We selected candidate representative markers of OS^HIGH^ cells by the following procedure. First, we excluded genes expressed in human normal tissues based on NCBI gene data and confirmed the expression status by RT‐PCR. Next, we selected genes expressed in OS^HIGH^ cells at higher levels than in OS^LOW^ cells. Among several candidates, we focused on *LIN28B*, which has been described as an oncogene in various human cancers.[15](#cas14229-bib-0015){ref-type="ref"} mRNA of *LIN28B* was highly expressed in OS13 bulk cells and in OS^HIGH^ cells (Figure [3](#cas14229-fig-0003){ref-type="fig"}A) and showed specific expression in the testis and placenta among normal human tissues (Figure [3](#cas14229-fig-0003){ref-type="fig"}B,C). *LIN28B* was not detected in human normal tissues other than the testis and placenta. Therefore, *LIN28B* could be categorized as a so‐called cancer/testis antigen.[3](#cas14229-bib-0003){ref-type="ref"} *LIN28B* was also expressed in several sarcoma cell lines (Figure [3](#cas14229-fig-0003){ref-type="fig"}D). Expression status of LIN28B protein in 40 sarcoma biopsy specimens was also assessed. Of the 40 specimens, 35 (87.5%) were graded as either low or high staining. High‐grade staining was observed in five of eight (62.5%) conventional osteosarcomas (Figure [3](#cas14229-fig-0003){ref-type="fig"}E, Tables [S2](#cas14229-sup-0001){ref-type="supplementary-material"} and [S3](#cas14229-sup-0001){ref-type="supplementary-material"}).

![Identification of LIN28B as a sarcoma‐initiating cells‐related gene. A, Quantitative RT‐PCR of LIN28B in clones with higher tumorigenesis as sarcoma‐initiating cells (osteosarcoma \[OS\]^HIGH^ cells) and clones with lower tumorigenesis as sarcoma‐initiating cells (OS^LOW^ cells). B, RT‐PCR of LIN28B in normal organs. Quantitative RT‐PCR of LIN28B in normal organs (C) and sarcoma cell lines (D). E, Immunohistochemical grading of sarcoma specimens. Representative sections of sarcoma specimens stained with an anti‐LIN28B antibody are shown. Normal testis tissue was used as a positive control. ES, epithelioid sarcoma; MFS, myxofibrosarcoma; OS, osteosarcoma; SS, synovial sarcoma. Original magnification, 200×](CAS-111-36-g003){#cas14229-fig-0003}

3.5. LIN28B is associated with sarcoma‐initiating ability and the inhibition of mitochondrial function {#cas14229-sec-0022}
------------------------------------------------------------------------------------------------------

To determine whether LIN28B has an effect on the tumorigenesis of OS13 cells, we inhibited *LIN28B* expression using shRNA. Expression of mRNA and protein of LIN28B was decreased in short hairpin LIN28B (shLIN28B) cells (Figure [4](#cas14229-fig-0004){ref-type="fig"}A,B). LIN28B knockdown cells showed decreased in vitro sphere formation (Figure [4](#cas14229-fig-0004){ref-type="fig"}C). Expression levels of mature let‐7a and let‐7g were markedly restored (Figure [4](#cas14229-fig-0004){ref-type="fig"}D) and resistance to Adriamycin decreased (Figure [4](#cas14229-fig-0004){ref-type="fig"}E). shLIN28B cells showed expression levels of stem cell‐related genes similar to those in short hairpin control (shControl) cells (Figure [4](#cas14229-fig-0004){ref-type="fig"}F).

![LIN28B is associated with the features of sarcoma stemness and dependency on aerobic glycolysis through suppression of oxidative phosphorylation. A, Quantitative RT‐PCR of LIN28B in short hairpin LIN28B (shLIN28B) and short hairpin control (shControl) cells. B, Western blotting of LIN28B protein in shLIN28B and shControl cells. β‐actin was used as a control. C, Number of spheres from shLIN28B and shControl cells (n = 15). D, Quantitative RT‐PCR of let‐7a and let‐7g. U6 snRNA was used as an internal control. E, Cell viability rates of shLIN28B and shControl cells in OS13 after Adriamycin (Sandoz) treatment (n = 3). Data represent means ± standard error (SE). \**P* \< .05, \*\*\**P* \< .001. N.S., not significant. F, Quantitative RT‐PCR of stem cell‐related genes. Data represent means ± SE. Percent changes of oxygen consumption rate (OCR) (G) and extracellular acidification rate (ECAR) (H) of osteosarcoma (OS)^LOW^, shLIN28B, and shControl cells relative to baseline measurements. Dotted lines indicate glucose injections. OS^LOW^, n = 7; shLIN28B, n = 7; and shControl, n = 8](CAS-111-36-g004){#cas14229-fig-0004}

We then addressed the metabolic status of shLIN28B cells. In the presence of glucose, OCR of shLIN28B cells markedly increased compared with that of shControl cells (Figure [4](#cas14229-fig-0004){ref-type="fig"}G). shLIN28B cells showed mitochondrial function and glycolysis similar to that of OS^LOW^ cells (Figure [4](#cas14229-fig-0004){ref-type="fig"}H). These results suggested that knockdown of LIN28B might switch the metabolic status of OS13 cells to that of OS^LOW^ cells.

3.6. Manipulation of aerobic glycolysis reduced tumorigenesis of OS13 cells and enhanced chemotherapeutic effect {#cas14229-sec-0023}
----------------------------------------------------------------------------------------------------------------

Because the proliferation of both OS^HIGH^ and OS^LOW^ cells depended on glycolysis and LIN28B might inhibit OXPHOS by upregulation of PDK1,[16](#cas14229-bib-0016){ref-type="ref"} we assessed the sphere‐formation ability of OS13 cells after treatment with the glycolysis inhibitors 2‐DG and DCA. Both inhibitors reduced the number of spheres in shControl and bulk OS13 cells (Figure [5](#cas14229-fig-0005){ref-type="fig"}A,B and Figure [S3](#cas14229-sup-0001){ref-type="supplementary-material"}A,B). Moreover, shLIN28B cancelled the inhibitory effect of DCA. These results suggested that the inhibition of glycolysis and the recovery of mitochondrial function decreased the sphere‐formation ability of OS13 cells expressing LIN28B. Cell viability after treatment with 2‐DG and DCA was greatly decreased in OS13 and MFH03 cells (Figure [5](#cas14229-fig-0005){ref-type="fig"}C,D). The other glycolysis inhibitors showed inhibitory effects on cell viability (Figure [S4](#cas14229-sup-0001){ref-type="supplementary-material"}A,B). This effect might be because the metabolism of sarcoma cells is highly dependent on glycolysis. Decreases of ATP production after exposure to glycolysis inhibitors were not dependent on LIN28B expression (Figure [S5](#cas14229-sup-0001){ref-type="supplementary-material"}A,B).

![Aerobic glycolysis inhibition reduced cell viability. Numbers of spheres of short hairpin LIN28B (shLIN28B), short hairpin control (shControl), and OS13 bulk cells with 2‐deoxyglucose (2‐DG) (A) and dichloroacetate (DCA) treatment (B) at a final concentration of 10 mM (shLIN28B and ShControl, n = 3; OS13 bulk, n = 6). Data represent means ± standard error (SE). Cell viability rates of OS13 and MFH03 cells with 2‐DG (n = 3) (C) and DCA treatment (n = 3) (D). Data represent means ± SE. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001. N.S., not significant](CAS-111-36-g005){#cas14229-fig-0005}

3.7. Glycolysis inhibitors enhanced chemotherapeutic effect and suppressed tumorigenesis in sarcoma cells {#cas14229-sec-0024}
---------------------------------------------------------------------------------------------------------

Osteosarcoma‐initiating cells are resistant to chemotherapy through LIN28B expression and depend on glycolysis to maintain tumor‐initiating ability (Figures [4](#cas14229-fig-0004){ref-type="fig"}E and [5](#cas14229-fig-0005){ref-type="fig"}A). To sensitize osteosarcoma‐initiating cells to chemotherapy, we assessed the effects of combination therapy that consisted of glycolysis inhibitors and Adriamycin, a key chemotherapy drug for osteosarcoma.

OS13 cells were initially treated with Adriamycin with or without 2‐DG in vitro. Results showed that 2‐DG could enhance the effects of low‐dose Adriamycin on OS13 cells (Figure [6](#cas14229-fig-0006){ref-type="fig"}A). Similar results to those in OS13 cells were also observed in MFH03 cells (Figure [6](#cas14229-fig-0006){ref-type="fig"}B). DCA also increased the effects of Adriamycin, although the effects were limited (Figure [6](#cas14229-fig-0006){ref-type="fig"}C,D).

![Glycolysis inhibitors increased sensitivity to chemotherapy and suppressed tumorigenesis of sarcoma cells in vitro and in vivo. Cell viability rates of OS13 (A) and MFH03 (B) bulk cells with Adriamycin (ADR; Sandoz) and 2‐deoxyglucose (2‐DG) treatment at 10 mM (n = 3). Cell viability rates of OS13 (C) and MFH03 (D) bulk cells with ADR and dichloroacetate (DCA) 10 mM treatment (n = 3). Data represent means ± standard error (SE). \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001. (E‐L) In vivo effect of glycolysis inhibitors and low‐dose Adriamycin. On Day 0, OS13 cells (1 × 10^6^) were xenografted into non‐obese diabetic scid IL2ry^null^ (NSG) mice. On the same day, PBS (E), 2‐DG (500 mg/kg, i.p.) (F, I, K) and DCA (200 mg/kg, i.p.) (G) were given 3 times per week for 6 weeks. ADR (1 mg/kg i.p.) was given once per week for 3 weeks (J, K); n = 5 (each group). Tumor volume of individual tumors (E‐G, I‐K) and the means of tumor volume (H, L) are shown](CAS-111-36-g006){#cas14229-fig-0006}

Finally, we assessed the in vivo effects of glycolysis inhibitors and Adriamycin, assuming an adjuvant setting, in OS13 cells. Compared with the PBS control group, the 2‐DG group did not show significant antitumor effects. In addition, rapid growth of the tumor was observed in the DCA group (Figure [6](#cas14229-fig-0006){ref-type="fig"}E--H). Low‐dose Adriamycin (1 mg/kg) alone did not show an antitumor effect on OS13 in vivo; however, a combination of Adriamycin and 2‐DG showed additional effects on the low‐dose Adriamycin and 2‐DG groups (Figure [6](#cas14229-fig-0006){ref-type="fig"}I--L). Most mice that received Adriamycin at the middle dose (3 mg/kg) and high dose (10 mg/kg) died as a result of toxicity before the treatment ended (Figure [S6](#cas14229-sup-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#cas14229-sec-0025}
=============

In the present study, a novel osteosarcoma cell line (OS13) was established and characterized as follows: (i) OS^HIGH^ cells derived from OS13 bulk cells showed higher levels of in vitro and in vivo tumorigenesis and chemoresistance; (ii) the metabolic status of OS^HIGH^ cells highly depended on glycolysis but not on OXPHOS; (iii) LIN28B was identified as a SIC‐related protein and expressed in 85% of sarcoma primary tissues; (iv) knockdown of LIN28B led to an increase in mitochondrial respiration; and (v) manipulation of aerobic glycolysis combined with chemotherapy decreased in vitro and in vivo tumorigenesis of OS13 cells.

Using next‐generation sequencing of OS^HIGH^ and OS^LOW^ cells, we identified *LIN28B* as a candidate SIC‐related gene. The *LIN2*8 family is a family of RNA‐binding proteins that regulate the degradation of let‐7 miRNAs and play key roles in many human malignancies.[15](#cas14229-bib-0015){ref-type="ref"}, [17](#cas14229-bib-0017){ref-type="ref"} A *LIN28* homolog, *LIN28B*, was first reported to be overexpressed in hepatocellular carcinoma (HCC).[18](#cas14229-bib-0018){ref-type="ref"} *LIN28B* expression promotes cancer development by suppression of the expression of let‐7 miRNAs in several human cancers including colon cancer,[19](#cas14229-bib-0019){ref-type="ref"} HCC,[16](#cas14229-bib-0016){ref-type="ref"}, [20](#cas14229-bib-0020){ref-type="ref"} B‐cell lymphoma,[21](#cas14229-bib-0021){ref-type="ref"} breast cancer,[22](#cas14229-bib-0022){ref-type="ref"} and multiple myeloma.[23](#cas14229-bib-0023){ref-type="ref"}

LIN28B mRNA was found to be expressed in various sarcomas, but was not detectable in normal organs other than the testis and placenta. In the testis, LIN28B protein was expressed in spermatogonia and spermatocytes but not in spermatids and sperm. This expression profile is the so‐called "cancer stem cell/testis antigen" pattern and is an ideal target for immunotherapy using peptide vaccination or adoptive cell transfer of genetically engineered exogenous T‐cell receptor‐expressing T cells (TCR‐T cells).[3](#cas14229-bib-0003){ref-type="ref"}, [24](#cas14229-bib-0024){ref-type="ref"}

The molecular mechanisms underlying attenuation of resistance to Adriamycin by knockdown of LIN28B remain unclear. However, LIN28 is known to mediate paclitaxel resistance through p21 and Rb expression and let‐7 miRNA inhibition, which increase RAS expression.[25](#cas14229-bib-0025){ref-type="ref"}, [26](#cas14229-bib-0026){ref-type="ref"} These mechanisms might confer resistance to Adriamycin through LIN28B expression in sarcoma cells.

In the present study, we showed that aerobic glycolysis was enhanced and mitochondrial function was impaired in OS^HIGH^ cells expressing LIN28B as SIC. Ma et al reported that LIN28B regulates aerobic glycolysis through downregulation of let‐7 miRNAs, upregulation of PDK1 and suppression of OXPHOS.[16](#cas14229-bib-0016){ref-type="ref"} Aguilar et al reported that glycolysis is essential for CIC.[8](#cas14229-bib-0008){ref-type="ref"} These findings also indicate that SIC of osteosarcoma might require predominant aerobic glycolysis, the so‐called Warburg effect.

We inhibited aerobic glycolysis using two glycolysis inhibitors. DCA is an inhibitor of PDK1 that regulates the phosphorylation of pyruvate dehydrogenase (PDH) and increases glucose uptake. PDH promotes the entry of pyruvate into the mitochondrial tricarboxylic acid cycle and suppresses production of lactate. 2‐DG is a glycolysis inhibitor that inhibits the activity of the first enzyme in the glycolysis pathway and totally blocks aerobic glycolysis. We found that DCA treatment decreased sphere‐formation ability and cell viability through restored mitochondrial capacity. In contrast, ATP levels and tumorigenesis of OS13 cells were greatly decreased by 2‐DG treatment. These results suggest that most OS13 cells depend on the glycolysis pathway for cell proliferation regardless of the fact that glycolysis yields a smaller amount of ATP compared with mitochondrial OXPHOS. This possibility is supported by the results of a previous study showing that cancer cells require not only rapid ATP synthesis but also various resultant metabolites generated by glycolysis for proliferation.[7](#cas14229-bib-0007){ref-type="ref"} For example, the accumulation of glycolytic intermediates promotes the pentose phosphate pathway, resulting in the generation of NADPH and ribose‐5‐phosphate. Ribose‐5‐phosphate is essential for the biosynthesis of nucleic acids.[27](#cas14229-bib-0027){ref-type="ref"}

In the in vivo study, a combination of 2DG and low‐dose Adriamycin showed antitumor effects against xenografted OS13 cells. These results are comparable with the in vitro study and suggested that glycolysis inhibitors might be useful for patients receiving chemotherapy for osteosarcoma.

In conclusion, we showed that LIN28B plays important roles in enhanced glycolysis in osteosarcoma‐initiating cells. Use of glycolysis inhibitors combined with chemotherapy might be a novel therapeutic approach for patients with osteosarcoma. Thus, the development of immunotherapy targeting LIN28B appears to be a good approach.
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